Royalty Report: Drugs, Disease, Biotechnology – Collection: 286247

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Disease
  • Biotechnology
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 286247

License Grant
University exclusively licensed to the Company certain intellectual property rights relating to GIAPREZA, including the exclusive rights to certain issued patents and patent applications covering GIAPREZA. Under the license agreement, we are obligated to use commercially reasonable efforts to develop, commercialize, market and sell GIAPREZA.
License Property
GIAPREZAâ„¢ is synthetic human angiotensin II (Rx).
Field of Use
GIAPREZAâ„¢ is a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock, approved by the U.S. Food and Drug Administration (“FDA”).   GIAPREZA was approved by the European Commission for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies.

IPSCIO Record ID: 26739

License Grant
Under a research agreement with the University, the Licensee funded T(beta)4 research for the Licensor and was granted a sole and exclusive world-wide license to any patents that resulted from such research.
License Property
T(beta)4 is used for the treatment of septic shock and associated syndromes, including ARDS.

Two U.S. patents have issued.  The first patent, No.  5,578,570, entitled Method of Treating Septic Shock Using T(beta)4 and the second patent, No. 5,593,964, entitled Method of Treating Septic Shock By Preventing Actin Polymerization.  The Company’s current primary business focus is the commercialization of Thymosin beta 4, a 43 amino acid peptide (T(beta)4).

Field of Use
The Licensee is concentrating its efforts on the use of T(beta)4 for the treatment of injured tissue and non-healing wounds to enable more rapid repair and/or tissue regeneration.

IPSCIO Record ID: 28154

License Grant
The Licensee entered into a patent License Agreement with the University. Pursuant to this License Agreement, the Licensor exclusively Licensed to the Licensee certain intellectual property rights, assigned to and controlled by the Licensor, relating to the potential use of angiotensin II for the treatment of hypotension.The Licensed intellectual property rights principally consist of three provisional patent applications filed in the United States, with worldwide rights to foreign filings on such applications.
License Property
Intellectual Property relating to the potential use of angiotensin II for the treatment of hypotension. Hypotension is low blood pressure.
Field of Use
The Licensed intellectual property rights principally consist of three provisional patent applications. The Company is currently developing LJPC-501, a proprietary formulation of angiotensin II, for the treatment of catecholamine-resistant hypotension.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.